|
|
|
| Clinical Value of Rho Kinase Inhibitor in the Treatment of Acute Left Heart Failure (ALHF) |
| ZHANG Shenghong, ZHU Fangyi, ZHU Cunkui |
| Qinghai Cardiovascular and Cerebrovascular Hospital, Qinghai Xining 810000, China |
|
|
|
|
Abstract Objective: To study the application value of Rho kinase inhibitor in the treatment of acute left heart failure (ALHF).Methods: Retrospective analysis was performed on 62 ALHF patients admitted from January 2019 to January 2020. The subjects were divided into control group and study group by referring to the random number table method, with 31 patients in each group. Both groups were given conventional treatment. The control group was treated with furtimox and spironolactone based on conventional treatment, while the study group was treated with furtimox, spironolactone and Rho kinase inhibitor (Fasudil hydrochloride) based on conventional treatment. Cardiac function index, myocardial enzyme spectrum index, total effective rate and adverse reaction rate were compared between the two groups before and after treatment. Results: Before treatment, there was no difference between the two groups in left ventricular end-systolic volum (LVSDV), left ventricular end-diastolic volume (LVEDV), left ventricular ejection fraction (LVEF), Creatine Kinase Isoenzyme-MB (CK-MB), lactate dehydrogenase, LDH and Aspartate aminotransferase (AST) levels (P>0.05).LVEF after treatment was higher, and LVSDV, LVEDV, CK-MB, LDH and AST levels were lower than those before treatment in both groups (P<0.05).After treatment, LVEF and total effective rate in the study group were higher than those in the control group, and LVSDV, LVEDV, CK-MB, LDH and AST levels were lower (P<0.05). The difference values between the two groups before and after treatment were compared, and the differences were statistically significant (P<0.05).There was no difference in the incidence of adverse reactions after treatment between the two groups (P>0.05). Conclusion: The application of Rho kinase inhibitor in ALHF treatment has a significant effect, can effectively improve the level of myocardial enzyme spectrum, and can promote the recovery of cardiac function, with fewer adverse reactions.
|
|
|
|
|
|
[1] 晏萍.左西孟旦联合托伐普坦治疗急性左心衰临床价值分析[J].医学理论与实践,2018,31(16):2402~2403.
[2] 唐正萍,李春慧,刘承,等.沙库巴曲缬沙坦联合环磷腺苷治疗急性左心衰疗效及对神经内分泌激素水平的影响[J].中国医院药学杂志,2020,40(9):1027~1032.
[3] 乔萍,曹峰,陈锋.西地兰联合美托洛尔治疗急性左心衰合并房颤临床效果分析[J].贵州医药,2020,44(4):569~571.
[4] 陈亚君,乔雯雯,薛鸿群.胺碘酮联合环磷腺苷葡胺及琥珀酸美托洛尔治疗急性左心衰伴房颤的疗效及对患者心功能和近期心血管事件的影响分析[J].四川解剖学杂志,2020,28(1):24~25.
[5] 井伟萌.硝普钠微量泵入联合西地兰治疗急性左心衰伴肺水肿的疗效观察[J].现代诊断与治疗,2019,30(23):4120~4122.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性心力衰竭诊断和治疗指南[J].中华心血管病杂志,2010,38(3):195~208.
[7] 付孝清,黎昌宏,谭杰.Rho激酶抑制剂联合呋塞米及螺内酯对急性左心衰患者心功能及血清AST、LDH、CK-MB水平的影响[J].心血管康复医学杂志,2019,28(4):461~466.
[8] 时璐璐,柳爱平,黄银平.对比西地兰与胺碘酮治疗快速型心房纤颤伴急性左心衰的临床效果[J].当代医学,2019,25(3):42~44.
[9] 欧红令,王永和.参芎葡萄糖注射液辅助治疗高血压急性左心衰及对血清代谢组学的影响研究[J].中国药师,2019,22(2):260~263,269. |
|
|
|
2021, Vol. 27 
